c-Met inhibitor SPH3348
Term · Oncology and biomedicine · MLC-T-ONC-012672
An orally bioavailable inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, c-Met inhibitor SPH3348 targets and binds to c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
| Identifier | MLC-T-ONC-012672 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012672",
"term": "c-Met inhibitor SPH3348",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, c-Met inhibitor SPH3348 targets and binds to c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/c-met-inhibitor-sph3348/"
}
Record 5,014 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.